MedPath

Effect of Food on the Pharmacokinetics of BI 1060469 (Formulation Tablet) in Healthy Male Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Registration Number
NCT02225626
Lead Sponsor
Boehringer Ingelheim
Brief Summary

Effect of food on the pharmacokinetics of BI 1060469 (formulation tablet) in healthy male subjects as well as to investigate pharmacokinetics, safety and tolerability

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
16
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
BI 1060469 fedBI 1060469tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administr
BI 1060469 fastedBI 1060469tablet, oral administration with 240 mL of water after an overnight fast of at least 10 h
Primary Outcome Measures
NameTimeMethod
AUC 0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)up to 6 days after last drug administration
Frequency of subjects with drug-related adverse eventsup to 7 days after last drug administration
Cmax (maximum measured concentration of the analyte in plasma)up to 6 days after last drug administration
Secondary Outcome Measures
NameTimeMethod
AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)up to 6 days after last drug administration

Trial Locations

Locations (1)

1333.44.1 Boehringer Ingelheim Investigational Site

🇩🇪

Ingelheim, Germany

© Copyright 2025. All Rights Reserved by MedPath